

The challenges of diversifying beyond CML

Elo Mapelu
Henzo Kenya

Henzo Kenya

- Henzo Kenya was formed 15 years ago
- In 2013 Kenya had a new government, and a new tax regime that required that all donated products be subjected to a new levy, RDL which was 1.5% of the value.
- There was need to have a bigger voice to push for preferential consideration for Glivec to be exempted from the new levy. - At the inception of KENCO




New Tax Provisions - Kenya

- The Kenya Finance Act 2013 introduced a Railway Development Levy of 1.5% on all imported goods in the country;
- This is to cover all imported goods including machinery & equipment by official Aid funded projects;
- Currently the National Treasury is working on revision of this provision not to include Aid funded projects.

 Taxwise

Henzo Kenya

- Joining forces with other like organizations for awareness, support, advocacy and research
- **NHIF is more impactful from breast cancer, cervical cancer advocacy point.**
- MoH has TWGs and invite KENCO to join, HENZO gets to join these critical TWGs- to provide independent and evidence-based guidance to the MoH in decision- and policy-making



Challenges:

- **Diverse conditions:** Various diseases with different treatment protocols
- **Number of patients:** CML patients are remarkably fewer
- **Lack of Support from pharma:** No commercial interest in CML as compared to others

Recently Henzo Kenya Joined ALAN

- Currently Implementing a project on Leukemia awareness and support for acute Leukemia patients **“CANCER CONTROL THROUGH AWARENESS CREATION, PATIENTS SUPPORT AND ADVOCACY– A MULTIFACETED APPROACH”**
- Provides a new funding stream

Challenges:

- Diverse Conditions: Acute Leukemia patients undergo a completely different treatment protocol.
- Disease progression: normally acute Leukemia patients are not as sociable due to frequent hospital visits and stigma

In conclusion:

- There are more gains that overcome the challenges noted above:
- Leukemia, and other haematological conditions create a bigger constituency of patients, HCPs and advocates who amplify the voices
- There may be pharma interest due to commercial potential of other haematological conditions.

Partnerships are the way to go!



Henzo Kenya is a member of :

